Search results
Showing 301 to 315 of 412 results for cardiovascular disease
Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 (TA971)
Evidence-based recommendations on remdesivir (Veklury) and tixagevimab plus cilgavimab (Evusheld) for treating COVID-19.
Lumella point-of-care test for assessing pre-eclampsia risk (MIB287)
NICE has developed a medtech innovation briefing (MIB) on Lumella point-of-care test for assessing pre-eclampsia risk .
Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (TA878)
Evidence-based recommendations on nirmatrelvir plus ritonavir (Paxlovid), sotrovimab (Xevudy) and tocilizumab (RoActemra) for treating COVID-19.
TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)
Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima, Inflectra). These drugs are for people with severe active ankylosing spondylitis or severe non-radiographic axial spondyloarthritis who have tried non-steroidal anti-inflammatory drugs (NSAIDs), but they have not worked.
What is the utility of routine cardiovascular evaluation for asymptomatic people with FH?
Recommendation ID CG71/6 Question What is the utility of routine cardiovascular evaluation for asymptomatic people with FH? Any...
Leadless cardiac pacemaker implantation for bradyarrhythmias (IPG626)
Evidence-based recommendations on leadless cardiac pacemaker implantation for bradyarrhythmias in adults. This involves inserting a device into the heart that helps it beat at a normal rate.
View recommendations for IPG626Show all sections
heterozygous FH. In addition, there is limited published evidence on the cardiovascular outcome of such patients treated with LDL...
This guideline sets out an antimicrobial prescribing strategy for acute sore throat. It aims to limit antibiotic use and reduce antimicrobial resistance. Acute sore throat is often caused by a virus, lasts for about a week, and most people get better without antibiotics. Withholding antibiotics rarely leads to complications.
Bosutinib for previously treated chronic myeloid leukaemia (TA401)
Evidence-based recommendations on bosutinib (Bosulif) for previously reated chronic myeloid leukaemia in adults.
Evidence-based recommendations on rimegepant (Vydura) for the acute treatment of migraine in adults.
Standards framework for shared-decision-making support tools, including patient decision aids (ECD8)
This framework sets out a series of standards to support people using patient decision aids (PDAs) in assessing the usefulness and quality of a PDA
COVID-19 rapid guideline: managing the long-term effects of COVID-19 (NG188)
This guideline covers identifying, assessing and managing the long-term effects of COVID-19, often described as ‘long COVID’. It makes recommendations on care in all healthcare settings for adults, children and young people who have new or ongoing symptoms 4 weeks or more after the start of acute COVID-19. It also includes advice on organising services for long COVID.
Attention deficit hyperactivity disorder: diagnosis and management (NG87)
This guideline covers recognising, diagnosing and managing attention deficit hyperactivity disorder (ADHD) in children, young people and adults. It aims to improve recognition and diagnosis, as well as the quality of care and support for people with ADHD.
Summary of the evidence on rifaximin for treating pouchitis to inform local NHS planning and decision-making
Dapagliflozin in triple therapy for treating type 2 diabetes (TA418)
Evidence-based recommendations on dapagliflozin (Forxiga) given with 2 other drugs for treating type 2 diabetes in adults.